Adivo
Martinsried
About Adivo
adivo is a veterinary biotechnology company developing therapeutic antibodies for pets. The focus is on the treatment of serious diseases in dogs with the potential to offer therapies for other species as well. The antibody selection is based on a new, fully synthetic, dog-specific drug library that can be used to isolate antibodies with optimal properties using phage display technology. adivo is a spin-off of MorphoSys AG. Many years of expertise in the development of human therapeutic antibodies transfer the adivo team into veterinary medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.8M
- Funding stage: M&A
- Last round: Grant (Oct 2021)
- Website: adivo.vet
- Phone: +49 (0) 89 588088-471
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/adivo-11058 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.